Psychopharmacology bulletin最新文献_第7页

Correction. 更正。

Psychopharmacology bulletin Pub Date : 2024-04-04

引用次数: 0

Zolpidem Stimulant Effect and Dependence: A Case Report on Intranasal Use. 唑吡坦的刺激作用和依赖性：关于鼻内用药的病例报告。

Psychopharmacology bulletin Pub Date : 2024-04-04

Branimir Margetić, Marina Alaber

{"title":"Zolpidem Stimulant Effect and Dependence: A Case Report on Intranasal Use.","authors":"Branimir Margetić, Marina Alaber","doi":"","DOIUrl":"","url":null,"abstract":"Zolpidem is a widely used hypnotic. Dependence on zolpidem due to the induction of euphoria is a rare condition, while intranasal misuse of zolpidem is a rather new phenomenon. We present the first case of a patient who developed zolpidem dependence, which was associated with the prompt onset of euphoria exclusively following intranasal use. Mr. A was a 51-year-old polydrug abuser with antisocial personality disorder and a physical dependence on zolpidem. Over several years, he consumed 500 mg of the drug daily, usually divided into 30 mg doses, exclusively via the nasal route because unlike the oral administration of the same dose of the drug, intranasal administration induced euphoria. Euphoric effects manifested 3-5 minutes after taking the drug, and pronounced withdrawal symptoms (i.e., profuse sweating, tremors, nausea, vomiting, diarrhea, and inability to drink and eat), present 7-8 hours after the use could disappear within 3-5 minutes upon drug re-administration. The dependence was managed through a slow tapering of the zolpidem use. Clinicians should be aware that intranasal use of zolpidem could be associated with euphoric effects and the development of addiction. The potential for misuse of zolpidem via the nasal route may be of interest for future research.","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"54 2","pages":"34-38"},"PeriodicalIF":0.0,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11003259/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140873724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Bell's Palsy Case Probably Related to Sertraline Use. 一个可能与使用舍曲林有关的贝尔氏麻痹病例

Psychopharmacology bulletin Pub Date : 2024-04-04

Mehmet Emin Ceylan, Barış Önen Ünsalver, Hatice Zeynep Ceylan

引用次数: 0

Clavulanic Acid Decreases Cocaine Cue Reactivity in Addiction-Related Brain Areas, a Randomized fMRI Pilot Study. 克拉维酸可降低成瘾相关脑区的可卡因线索反应性，一项随机 fMRI 试验研究。

Psychopharmacology bulletin Pub Date : 2024-04-04

Linda S Callans, Helene Philogene-Khalid, Kanchana Jagannathan, Ronan Cunningham, Daohai Yu, Xiaoning Lu, M Ingre Walters, Mary F Morrison

{"title":"Clavulanic Acid Decreases Cocaine Cue Reactivity in Addiction-Related Brain Areas, a Randomized fMRI Pilot Study.","authors":"Linda S Callans, Helene Philogene-Khalid, Kanchana Jagannathan, Ronan Cunningham, Daohai Yu, Xiaoning Lu, M Ingre Walters, Mary F Morrison","doi":"","DOIUrl":"","url":null,"abstract":"Background: Preclinical studies show that clavulanic acid (CLAV) inhibits cocaine self-administration. This study investigates the effect of CLAV on regions of brain activation in response to cocaine cues during functional magnetic resonance imaging (fMRI) in participants with cocaine use disorder (CUD).Methods: A double-masked, placebo-controlled clinical trial with thirteen individuals with severe CUD who were randomized to treatment with CLAV (N = 10, 9 completers) 500 mg/day or matched placebo (PBO) (N = 3) for 3 days. fMRI was used to assess brain reactivity to 18 alternating six-second video clips of cocaine or neutral scenes. In this paradigm, participants were exposed to three different stimulus conditions: NEUTRAL, WATCH (passive watching), and DOWN (actively inhibiting craving while watching).Results: Participants who received CLAV demonstrated a significant reduction in brain activity in the anterior cingulate gyrus (p = 0.009) and the caudate (p = 0.018) in response to DOWN cocaine cues. There was a trend toward lessened cue reactivity in other regions implicated in CUD.Conclusion: CLAV reduced the response of the brain regions associated with motivation and emotional response during the DOWN condition compared to PBO, suggesting CLAV may strengthen voluntary efforts to avoid cocaine use. This pilot data supports the use of CLAV for CUD. (Trial registered in ClinicalTrials.gov NCT04411914).","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"54 2","pages":"8-14"},"PeriodicalIF":0.0,"publicationDate":"2024-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11003254/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140870620","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clozapine Prescripers-Dogmatic or Pragmatic? 开氯氮平处方的人--教条主义还是实用主义？

Psychopharmacology bulletin Pub Date : 2024-04-04

Ahmed Naguy, Hessa Alhazeem

引用次数: 0

Case Report on High Dose Lithium Treatment for Post-COVID Depression, Recurrent Fevers, and Skin Lesions. 大剂量锂治疗宫颈癌后抑郁、反复发烧和皮肤病变的病例报告。

Psychopharmacology bulletin Pub Date : 2024-04-04

Lila Elizabeth Massoumi, Alan Rosenbaum

引用次数: 0

A Comprehensive Review of Solriamfetol to Treat Excessive Daytime Sleepiness. 治疗日间过度嗜睡的 Solriamfetol 全面回顾。

Psychopharmacology bulletin Pub Date : 2024-03-04

Mitchell C Fuller, Samuel Carlson, Haley Pysick, Vince Berry, Andrew Tondryk, Hayden Swartz, Elyse M Cornett, Adam M Kaye, Omar Viswanath, Ivan Urits, Alan D Kaye

{"title":"A Comprehensive Review of Solriamfetol to Treat Excessive Daytime Sleepiness.","authors":"Mitchell C Fuller, Samuel Carlson, Haley Pysick, Vince Berry, Andrew Tondryk, Hayden Swartz, Elyse M Cornett, Adam M Kaye, Omar Viswanath, Ivan Urits, Alan D Kaye","doi":"","DOIUrl":"","url":null,"abstract":"Purpose of review: This is a comprehensive review of the literature regarding the use of Solriamfetol for excessive daytime sleepiness. It covers the background and current therapeutic approaches to treating excessive daytime sleepiness, the management of common comorbidities, and the existing evidence investigating the use of Solriamfetol for this purpose.Recent findings: Excessive daytime sleepiness leads to worse quality of life, a medical sequela and significant economic cost. There are multiple phenotypes of excessive daytime sleepiness depending on the comorbidity making treatment challenging. Due to the complexity of etiology there is not a cure for this ailment. Solriamfetol is a norepinephrine/dopamine dual reuptake antagonist that can be used to manage daytime sleepiness. Solriamfetol was first approved by the FDA in 2018 for use in excessive daytime sleepiness associated with obstructive sleep apnea and narcolepsy. Ongoing literature has proved this drug to be a safe and effective alternative pharmacotherapy.Summary: Recent epidemiological data estimate up to one-third of the general adult population suffers from excessive daytime sleepiness. There is no cure to daytime somnolence and current pharmacotherapeutic regimens have worrisome side effect profiles. Solriamfetol is a new class of drug that offers a safe and effective alternative option for clinical providers treating excessive daytime sleepiness.","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"54 1","pages":"65-86"},"PeriodicalIF":0.0,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10913864/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140051438","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New-Onset Prolonged Psychosis Following Synthetic Cannabinoid Use in an Older Patient: A Case Report. 一名老年患者使用合成大麻素后新发的长期精神病：病例报告。

Psychopharmacology bulletin Pub Date : 2024-03-04

Ahmed Alhassan, Srihari R Prahad, Bradley G Burk, Rachel E Fargason, Badari Birur

{"title":"New-Onset Prolonged Psychosis Following Synthetic Cannabinoid Use in an Older Patient: A Case Report.","authors":"Ahmed Alhassan, Srihari R Prahad, Bradley G Burk, Rachel E Fargason, Badari Birur","doi":"","DOIUrl":"","url":null,"abstract":"Synthetic cannabinoids (SCs), a class of new psychoactive substances (NPS) commonly known as \"spice,\" has rapidly gained popularity and become the most ubiquitous NPS on the illegitimate drug market. SCs, unlike natural cannabis (NC), are not controlled by international drug conventions, posing a significant risk to public health. These substances are easily accessible, relatively inexpensive, and challenging to detect in routine drug screenings. The existing literature provides strong evidence of an association between NC use and psychosis, but there is significantly less data on SC psychosis. We present a clinical case report of a 51-year-old African American female with no known psychiatric history who was admitted to the inpatient psychiatric unit after reported paranoia and altered mental status for the preceding six days. During hospitalization, she exhibited disorganization, persecutory delusions, extreme agitation, and bizarre behaviors that included the concealment of a set of stolen keys in her vagina, necessitating an ethics consult. After consideration of differentials, the patient was diagnosed with substance-induced psychotic disorder secondary to SC. The patient was stabilized on 3 mg Risperidone at bedtime. After 16-day hospitalization, she reached her baseline and later revealed that she had recently smoked SC for the first time. The primary goal of this case is to highlight the sequelae of SC-associated psychosis. A SC-associated psychosis could drastically vary from NC and is often undetectable on a typical UDS, which may result in a lifelong primary psychotic disorder misdiagnosis.","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"54 1","pages":"33-39"},"PeriodicalIF":0.0,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10913866/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140051477","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Comprehensive Review of Lemborexant to Treat Insomnia. 全面回顾治疗失眠的 Lemborexant。

Psychopharmacology bulletin Pub Date : 2024-03-04

Mitchell C Fuller, Samuel F Carlson, Chris Grant, Vince Berry, Marko Ivancich, Elyse M Cornett, Adam M Kaye, Omar Viswanath, Ivan Urits, Sahar Shekoohi, Alan D Kaye

{"title":"A Comprehensive Review of Lemborexant to Treat Insomnia.","authors":"Mitchell C Fuller, Samuel F Carlson, Chris Grant, Vince Berry, Marko Ivancich, Elyse M Cornett, Adam M Kaye, Omar Viswanath, Ivan Urits, Sahar Shekoohi, Alan D Kaye","doi":"","DOIUrl":"","url":null,"abstract":"Purpose of review: This is a comprehensive review of the literature regarding Lemborexant for the treatment of insomnia. It covers the background and management of insomnia and then reviews the body of existing evidence evaluating the use of Lemborexant for this purpose.Recent findings: Insomnia leads to significant decreased in quality of life and economic burden due to decreased workplace performance and increased health care costs. Insomnia manifests as a single common pathway of hyperarousal due to a highly complex network of interactions between activation of the sympathetic system and the endocrine system. Lemborexant is a dual orexin 1/2 antagonist that blocks cortical arousal and promotes sleep state transition. Lemborexant was approved by the FDA in 2019 for use in insomnia. It belongs to a class of orexin neuropeptide inhibitors that is growing in popular clinical application.Summary: Insomnia is a crippling disorder of the sleep wake cycle that drives significant morbidity and mortality in the United States. It carries a high societal and economic toll due to direct and indirect effects to the healthcare system. Lemborexant is a new addition to the orexin antagonist class of drugs that already includes Almorexant and Suvorexant that has superior pharmacokinetic properties. While Lemborexant does have a mild side effect profile, its clinical safety and efficacy make it a promising insomnia drug of the future.","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"54 1","pages":"43-64"},"PeriodicalIF":0.0,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10913865/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140051437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

A Pilot Study to Explore the Effect of Long Acting Injectable Antipsychotics on Aggression. 探索长效注射抗精神病药物对攻击行为影响的试点研究。

Psychopharmacology bulletin Pub Date : 2024-03-04

Tiffany M Hopkins, O Greg Deardorff, Yifei Liu, Megan G Trout, Roger W Sommi, Niels C Beck

{"title":"A Pilot Study to Explore the Effect of Long Acting Injectable Antipsychotics on Aggression.","authors":"Tiffany M Hopkins, O Greg Deardorff, Yifei Liu, Megan G Trout, Roger W Sommi, Niels C Beck","doi":"","DOIUrl":"","url":null,"abstract":"Objectives: To explore the effect of switching from an oral antipsychotic to a long-acting injectable (LAI) antipsychotic on aggression, in terms of the changes of verbal and physical aggression, interventions required, self-injurious behavior, use of seclusion or restraint, antipsychotic medication refusal, and use of antipsychotics as needed (PRN).Methods: This was a retrospective chart review at a long-term state forensic psychiatric facility. Patients treated with an oral antipsychotic for at least 6 months and then switched to a LAI antipsychotic for an additional 6 months during an 80-month period were included.Results: Out of 70 patients evaluated, 18 were the study subjects. The median age of the cohort was 38 years with a majority being male. Of the seven patients who had an incident of aggression, two had an increase in aggressive incidents following the switch, three had a decrease, and two had no change. Thirty-six interventions occurred while patients were on an oral antipsychotic, which decreased by 30.6% to 25 interventions after the switch. Three patients had an incident of self-injurious behavior, and 6 patients required restraints/seclusions. Of the eight patients who had retrievable medication refusal and antipsychotic PRN use information, five had a decrease in antipsychotic medication refusals and five had an increase in PRN antipsychotic use after the switch.Conclusion: The switch from an oral antipsychotic to a LAI antipsychotic did not appear to significantly increase or decrease incidents of aggression or self-injurious behavior, but seemed to decrease the number of restraints/seclusions required.","PeriodicalId":94351,"journal":{"name":"Psychopharmacology bulletin","volume":"54 1","pages":"18-24"},"PeriodicalIF":0.0,"publicationDate":"2024-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10913868/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140051440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0